All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On Monday 3 December 2018, during the 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA, Laurie Sehn from British Columbia Cancer Agency, Vancouver, CA, presented the results of the phase III trial GOYA (Abstract #783; Oral Session #626).
GOYA (NCT01287741) was an international, open-label, randomized, phase III trial that compared the efficacy and safety of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to obinutuzumab (G) plus CHOP in previously untreated patients diffuse large B-cell lymphoma (DLBCL) patients. In the primary analysis of the GOYA trial, there was no significant difference in the three-year PFS of patients receiving R-CHOP to those receiving G-CHOP. In this current secondary analysis, the assessed endpoints were investigator-assessed (INV) progression-free survival (PFS), and overall survival (OS) in patients receiving six cycles of CHOP (CHOP6) versus eight cycles of CHOP (CHOP8). Secondary endpoint was safety of CHOP6 versus CHOP8.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox